ALPN-202 With PD-1 Inhibition in Advanced Malignancies

Phase 1

Terminated

• Conditions: Advanced Solid Tumor; Lymphoma
• Interventions: Drug: ALPN-202; Drug: pembrolizumab KEYTRUDA®

• Registration Number: NCT04920383
• Lead Sponsor: Alpine Immune Sciences, Inc.

Brief Summary

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-06-03
• Study First Submitted QC: 2021-06-03
• Study First Posted: 2021-06-09
• Study Start: 2021-06-22
• Primary Completion: 2022-11-08
• Study Completion: 2023-02-28
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-29
• Last Update Posted: 2024-03-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

• Adult 18 to 80 years old at screening

• Pathologically confirmed, locally advanced or metastatic unresectable solid tumor, or Hodgkin or Non-Hodgkin lymphoma (including transformed lymphoma) of an acceptable histology:

  1. that is eligible for treatment with a PD-1 or PD-L1 inhibitor, or
  2. that is refractory or resistant to standard therapy, or
  3. for which standard or curative therapy is not available.

• Have received ≥ 2 prior systemic anti-cancer therapies (lymphoma subjects only)

• Protocol-defined measurable disease

• Available tumor biopsy representative of current disease

• ECOG performance status grade 0-1

• Life expectancy of ≥ 3 months

• Recovery to Grade ≤ 1 for any non-laboratory toxicity resulting from previous anticancer therapy prior to first dose of ALPN-202 (except alopecia, hearing loss, Grade ≤ 2 neuropathy, or endocrinopathy managed with replacement therapy)

• Adequate baseline hematologic, renal, hepatic and cardiac function

Read More

Exclusion Criteria

• Any history of ≥ Grade 3 immune-related adverse event (irAE) requiring discontinuation from treatment or any history of a cardiovascular irAE

• Active or prior pneumonitis or interstitial lung disease

• Presence of any active central nervous system metastases

• Prior organ allograft or allogeneic hematopoietic stem cell transplantation

• Any other serious or uncontrolled health condition, which, in the opinion of the Investigator, would place the subject at undue risk from the study, impair the ability of the subject to receive protocol specified therapy, or interfere with the interpretation of study results.

• Receipt of any protocol-restricted therapy within the timeframes indicated:

  1. Checkpoint inhibitors, including PD-(L)1 (e.g., pembrolizumab, nivolumab, cemiplimab, avelumab, durvalumab), CTLA-4 (e.g., ipilimumab, tremelimumab), and Lag-3 (e.g., relatlimab), costimulatory agonists (including but not limited to CD28, CD134 (OX40), CD137 (4-1BB)): 3 months (135 days for atezolizumab)
  2. Chemotherapy, small molecule anticancer agents (e.g., kinase inhibitors), or radiation: 2 weeks
  3. Other monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, antibody-like drugs, cytokines, cell therapies, or radioimmunoconjugates: 4 weeks

• Any active, known, or suspected autoimmune disease

• Systemic treatment with corticosteroids (> 10 mg/day prednisone) or other immunosuppressive medication

• Any second malignancy active within the previous 3 years

• Active infection requiring therapy at the time of the first dose of ALPN-202.

• Known seropositivity for or active infection by human immunodeficiency virus, hepatitis B or C, or or Severe Acute Respiratory Syndrome Coronavirus 2.

• Known allergies, hypersensitivity, or intolerance to ALPN-202 or excipients in the drug product formulation.

• History of Grade 4 infusion-related, anaphylactic or allergic reaction to any previous Fc-based protein therapy.

• Any serious or uncontrolled cardiovascular condition, including but not limited to:

  1. Any history of myocarditis of any etiology
  2. History of New York Heart Association Class III or IV congestive heart failure, myocardial infarction, unstable angina, cerebrovascular accident, cardiac hospitalization, or other acute uncontrolled heart disease within 6 months of scheduled C1D1
  3. Left ventricular ejection fraction < 45% on screening echocardiogram
  4. Any clinically significant findings on screening EKG such as atrial or ventricular arrythmia (other than sinus tachycardia) or AV conduction abnormality such as left bundle branch block (such subjects may be enrolled after cardiology clearance and Medical Monitor approval)

• Has received prior radiotherapy within 2 weeks of start of study treatment, or have had a history of radiation pneumonitis

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dose Escalation and Expansion	ALPN-202	ALPN-202 + pembrolizumab KEYTRUDA®
Dose Escalation and Expansion	pembrolizumab KEYTRUDA®	ALPN-202 + pembrolizumab KEYTRUDA®

Primary Outcome Measures

Name	Time	Method
Dose-limiting Toxicities (DLTs)	Up to 6 weeks following study day 1	Incidence of DLTs
Laboratory Abnormalities	Up to 30 days after last dose of study drug	Type, incidence, and severity of laboratory abnormalities
Adverse Events (AEs)	30 days after last dose of study drug	Type, incidence, severity, and seriousness of AEs

Trial Locations

Locations (5)

Investigational Site (212); 🇺🇸 Boston, Massachusetts, United States

Investigational Site (213); 🇺🇸 Atlanta, Georgia, United States

Investigational Site (301); 🇺🇸 Grand Rapids, Michigan, United States

Investigational Site (203); 🇺🇸 Nashville, Tennessee, United States

Investigational Site (215); 🇺🇸 San Antonio, Texas, United States